News FDA approves Allergan's migraine tablet ahead of AbbVie merg... Allergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with or without aura.
News FDA approves Lilly's new migraine attack drug, rival from Al... The FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms should they feel an attack coming on.
News Lundbeck to acquire Alder, and migraine drug, for $1.95bn Lundbeck is to acquire Alder BioPharmaceuticals and its late-stage migraine drug eptinezumab in a deal worth up to $1.95 billion.
News Boehringer transfers schizophrenia DTx selling rights to Cli... Boehringer has altered the terms of its digital therapeutic alliance with Click on schizophrenia app CT-155, taking a more strategic investor role.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
